Follicular lymphoma

• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 "Diffuse large B-cell lymphoma (DLBCL)"
• A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting
  2024-516869-36-00 1 2025-02-17 "Relapsed or refractory B-cell malignancies: chronic lymphocy"
• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign … Recruiting
  2022-501374-19-00 4 2022-09-16 "Aggressive and Indolent B-cell Malignancies (mantle cell lym"
• A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lympho … Recruiting
  2025-521205-41-00 4 2026-03-12 "Diffuse large B-cell lymphoma NOS, follicular lymphoma Grade"
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 "High-grade B-cell lymphoma (HGBL)"
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants … Recruiting
  2024-519152-82-00 5 2025-09-03 "Relapsed/Refractory Follicular Lymphoma"
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 … Recruiting
  2023-508196-36-00 4 2025-05-27
• A trial to learn how well surovatamig (AZD0486) works and how safe it is in adults with certain blood cancers Recruiting
  2023-505789-27-00 4 2025-04-14 "Relapsed or Refractory Non-Hodgkin Lymphoma"
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 "Untreated FLIPI 2-5 Follicular Lymphoma"
• A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part … Recruiting
  2022-503092-28-00 5 2024-01-08 "Relapsed/Refractory Follicular Lymphoma"
• DK-CLIC-1901 CAR T-cells for treatment of patients with relapsed/refractory CD19 positive hematological malignancies (DAN-CART 1901) Recruiting
  2024-515174-27-00 4 2022-10-03 "Acute Lymphoblastic Leukemia and B-cell Non Hodgkin Lymphoma"
• Clinical trial with Mosunetuzumab and Zanubrutinib in patients with relapsed/refractory follicular lymphoma Recruitment ended
  2023-506049-52-00 4 2024-10-28
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Recruitment ended
  2023-506906-38-00 5 2024-05-23 "Follicular Lymphoma"
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Recruitment ended
  2024-511594-30-00 5 2023-02-23 "Relapsed/Refractory Follicular Lymphoma"
• A Study to Evaluate Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Len … Recruitment ended
  2023-505807-21-00 5 2021-11-16 "Relapsed/refractory follicular lymphoma"
• Study of Rapcabtagene autoleucel (YTB323) in adult patients with CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Recruitment ended
  2023-507062-34-00 7 2020-08-07 "High-Risk large B-Cell lymphoma"
• A Study Evaluating the Safety, Pharmacokinetics (what the body does to a drug), and Efficacy of Mosunetuzumab given subcutaneously (SC) or i … Recruitment ended
  2023-507236-20-00 9 2020-07-28 "Follicular Lymphoma (FL)"
• MB-CART19.1 r/r CD19+ BCM Recruitment ended
  2024-513334-38-00 1 2018-05-15 "Refractory/relapsed B-NHL"
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib Recruitment ended
  2023-507329-40-00 6 2017-09-28 "1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Wa"
• A Study to Learn About How Different Formulations of the Medicine Called Mevrometostat are Taken up Into the Blood in Healthy Adult Particip … Ended
  2024-516907-18-00 3 2024-11-20 "Small cell lung cancer, Castration-resistant prostate cancer"
• A Study in Healthy Adult Male Participants to Evaluate the Metabolism of [14C]PF-06821497 Ended
  2023-508371-36-00 3 2024-07-15 "small cell lung cancer (SCLC), castration resistant prostate"
• Efficacy and safety of tisagenlecleucel in adult patients with refractory or relapsed follicular lymphoma Ended
  2023-508127-13-00 4 2019-01-25 "Adult patients with refractory or relapsed follicular lympho"

Showing 1–22 of 22 trials